A very different way to project risk for clinically significant prostate cancer?

We don’t want to suggest that the recent paper by a Japanese research team in the journal Andrology is necessarily going to revolutionize the diagnosis of clinically significant prostate cancer. A great deal more work would be required to justify the hypothesis that they put forward. On the other hand, their hypothesis is definitely interesting. … READ MORE …

Androgen supplementation and risk for prostate cancer

A new paper from a research team in Seattle probably has limited relevance to our understanding of the real risks associated with androgen supplementation and subequent diagnosis of prostate cancer (or other prostate disorders) — even though it was a randomized, double-blind clinical trial. … READ MORE …